Study to understand clinical characteristics, treatment pathway in chronic lymphocytic leukemia - CREEK

Inclusion Criteria

• Inclusion Criteria:
• • Primary diagnosis of Chronic Lymphocytic Leukemia (CLL)
• • Initiated CLL treatment (including 1st line, 2nd line, or Subsequent lines of treatment) within the period between 01 June 2016, and 12 months before data collection
• - For GCC pilot cohort patients: treatment-naive CLL patients diagnosed between 01 June 2016, and 12 months before data collection.
• • Available medical records at the participating site reflecting at least 12 months of follow-up after starting on treatment (except in the case of the participant death within one year following treatment initiation).
• • Provision of informed consent by the patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver was granted), according to local regulations.
• • Adult male or female ≥18 years old at the time of diagnosis or according to the age of majority as defined by local regulations).
• Exclusion Criteria:
• • Failure to meet one or more of the inclusion criteria.
• • Any diagnosis of B-cell malignancies other than CLL.
• • Current or prior use of “acalabrutinib” treatment.
• • Currently/previously receiving treatment in an interventional clinical trial at the time of entry into this study for indications CLL.